cell heterogeneity as observed herein, could limit GSI efficacy. These data suggest a breast T-ISC hierarchy in which distinct pathways drive developmentally related subpopulations with different anti-cancer drug responsiveness.
Increasing evidence suggests that stem-like cells mediate cancer therapy resistance and metastasis. Breast tumour-initiating stem cells (T-ISC) and Notch target genes. We show N1-ICD transactivates SOX2 to increase sphere formation, ALDH1þ and CD44 þ CD24 lowþ cells. Gamma secretase inhibitors (GSI) reduced sphere formation and xenograft growth from CD44 þ CD24 lowþ cells, but CD44 þ CD24 neg were resistant. While GSI hold promise for targeting T-ISC, stem cell heterogeneity as observed herein, could limit GSI efficacy. These data suggest a breast T-ISC hierarchy in which distinct pathways drive developmentally related subpopulations with different anti-cancer drug responsiveness.
INTRODUCTION
Many cancers appear to be driven by stem-like cells that selfrenew, differentiate to yield heterogeneous progeny and survive adverse microenvironments . That these may also initiate metastasis has driven efforts to identify and characterize them. Tumour-initiating stem cell (T-ISC)-enriched populations have been identified in various cancers by discrete surface markers and by their ability to generate tumour spheres and xenograft tumours with high frequency (Frank et al, 2010; Magee et al, 2012; O'Brien et al, 2009 ). Elegant lineage tracing experiments recently provided compelling evidence for the cancer stem cell model (Chen et al, 2012; Driessens et al, 2012; Schepers et al, 2012) . In primary breast cancers, CD44 þ CD24 neg/ low ESA þ cells were enriched for xenograft formation compared to bulk tumour cells (Al Hajj et al, 2003) . Aldehyde dehydrogenase 1 (ALDH1) activity also marks breast cancer cells enriched for stem cell properties and those with both ALDH1 þ and CD44 þ CD24 neg/low are most tumourigenic, but infrequent (<1%; Ginestier et al, 2007) .
For cancers of breast, pancreas, prostate, head and neck and colon, the T-ISC phenotype consistently includes surface CD44 þ expression (Al Hajj et al, 2003; Hurt et al, 2008; Li et al, 2007; O'Brien et al, 2007; Prince et al, 2007) . CD44 expression has been associated with poor prognosis and metastasis, supporting the idea that stem-like cells generate metastases (Liu et al, 2010; Shipitsin et al, 2007; Yang et al, 2008) . In contrast, the relationship between surface CD24 expression and stemness differs between solid tumours. Overexpression of this glycosylated surface protein increases cancer cell proliferation and migration (Aigner et al, 1998) . While surface CD24 is observed in subsets of T-ISC from liver (Lee et al, 2011) , colon (Yeung et al, 2010) and pancreas (Li et al, 2007) , the T-ISC phenotype described for primary breast cancers show negative or low level surface CD24 (CD44 þ CD24 neg/low ; Al Hajj et al, 2003) .
This contrasts with normal mammary progenitors cells, which express CD24 (Pece et al, 2010; Spike et al, 2012) . It is noteworthy that CD24 þ cells are increased in metastatic compared to primary breast cancers (Shipitsin et al, 2007) . Populations surviving chemotherapy and radiation appear to be enriched for T-ISC (Calcagno et al, 2010; Li et al, 2008; Tanei et al, 2009) , possibly due to membrane transporters, greater quiescence and enhanced DNA repair, permitting T-ISC regeneration (Frank et al, 2010; O'Brien et al, 2009 ). Thus, identification and interdiction of T-ISC specific pathways may permit greater anti-cancer treatment efficacy. To date, the difficulty of isolating viable T-ISC from solid tumours in sufficient quantity to permit their molecular characterization has limited development of T-ISC-directed therapies that circumvent drug resistance or induce differentiation. Breast cancer cell lines have been shown to contain T-ISC analogous to those in primary breast cancers, permitting isolation of the large numbers of T-ISC required for functional characterization (Charafe-Jauffret et al, 2009; Fillmore & Kuperwasser, 2008) .
Stem-like cell subsets within a cancer may vary not only in their self-renewal potential, but also in their ability to successfully engage different metastatic niches. While T-ISC or a sub-population thereof have been broadly posited as giving rise to metastasis, relatively few experimental models have addressed this directly. ALDH1 þ CD44 þ CD24 neg subpopulations in breast cancer lines yielded more xenograft metastasis than ALDH1 -CD44 low/À CD24 þ (Croker et al, 2008) , but metastatic potential was not limited to the very low minority ALDH1 þ population. While increasing data indicate the presence of functional heterogeneity within T-ISC enriched populations in other tumours (Hermann et al, 2007; Lee et al, 2011; Pang et al, 2010; Yang et al, 2008) , identification and characterization of mammary T-ISC subsets that consistently metastasize or that mediate therapy resistance presents a challenge. The present study was undertaken to identify discrete subsets among T-ISC of the most deadly form of breast cancer: that lacking estrogen and progesterone receptors and HER2 amplification (so called triple negative-hereafter TNBC). We postulated that, as for normal stem cells, primary TNBC-derived cultures and immortal lines might exhibit an aberrant T-ISC hierarchy with precursor/progeny populations that differ in molecular pathways conferring self-renewal, tumourigenicity and metastatic potential.
Here we demonstrate a hierarchical relationship between distinct subsets within CD44 shown to directly transactivate SOX2 to drive self-renewal. Although Notch has been previously implicated in breast cancer stem cell self-renewal (Harrison et al, 2010; McGowan et al, 2011; Sansone et al, 2007 ) the CD44 þ CD24 neg T-ISC subpopulation was unaffected by Notch inhibition in 2D culture, sphere and xenograft assays, revealing a heretofore unappreciated heterogeneity in GSI responsiveness in T-ISC.
RESULTS
A subset of TNBC lines and patient-derived dissociated tumours contain two distinct stem cell populations The CD44 þ CD24 neg/low breast cancer population was shown to be enriched for cancer initiating stem cells (Al Hajj et al, 2003) .
Here we investigated the potential existence within this phenotype of subsets with differing self-renewal and tumour initiating abilities. Surface CD44 and CD24 expression were assayed in established breast cancer lines and in seven patientderived TNBC dissociated tumour cultures (DTs). DTs were used at early passage and their morphologic and molecular characteristics, including gene expression profiling, resemble the original patient tumours from which they were derived (Bayliss et al, 2007) . Although all DTs were derived from primary TNBC, their gene expression profiles vary: DT-28 has a basal/epithelial phenotype by PAM-50; DT-22 and DT-25 (as for MDA-MB-231) are basal; DT16 is luminal B and DT-13 localizes to the HER2 þ expression profile. Notably, most of the 14 estrogen receptor (ER) negative lines and DTs assayed show a high percent of CD44 þ CD24 neg/low cells, while ER positive lines (as described (Charafe-Jauffret et al, 2009; Fillmore & Kuperwasser, 2008) ), vary in CD44 staining and have higher CD24 than most ER negative cultures (Fig 1A (right) and Supporting Information Fig S1) . Interestingly, a minority of TNBC lines and DTs tested (BT-20, BT-549 and DT-28), showed higher CD24 expression and few if any CD24 negative cells (Supporting Information Fig S1) . Thus, the most common CD44 þ CD24 neg/low phenotype of TNBC investigated herein is not the only pattern observed within TNBC. MDA-MB-231, DT-22 and DT-25 ( Fig. 1 and Supporting Information Fig S1) Research Article www.embomolmed.org Functional heterogeneity in breast CSCs population with low level surface CD24 positivity or CD44 þ CD24 lowþ (<20%) cells (see Fig 1A) . Failure to stain surface CD24, or CD24-negativity (CD24 neg ), was defined by the gate set from unstained controls. While most TNBC showed a subset of cells with low level surface CD24 positivity (CD24 lowþ ) the extent of CD24 staining was considerably less than that in ER positive lines (Fig 1A, right) . Admixture of MCF-7 and MDA-MB-231 shows how these differ in CD24 staining and identifies the subset defined as CD24 lowþ in TNBC lines (see Supporting
Information Fig S1D) . The expression of CD44 and CD24 markers in the DT cultures was highly stable over multiple passages, as was their growth rate. Notably the proportion of CD44 þ CD24 lowþ cells in passage four DT-22 was similar to passage 11 (representative data, Fig 1B) . Likewise, CD44 and CD24 expression was similar in DT-25 at passages three and nine (Supporting Information Fig S2A) . (Fig. 1E ). Surface epithelial specific antigen þ (ESA, also known as EpCAM; Al Hajj et al, 2003) and ALDH1 þ populations (Ginestier et al, 2007) have also been shown to define minority populations enriched for T-ISC. In DT-22 and MDA-MB-231, the proportions of ALDH1 þ and of ESA þ cells were low (1-2% and 2-5%, respectively) (Supporting Information Fig S2C) (Fig 3A and C) . The reduced tumour initiating ability of CD44 þ CD24 neg DT-22 was reproducibly evident at several different cell numbers injected (Fig 3A and B) . One hundred CD44 þ CD24 lowþ DT-22 cells formed tumours in only 3/8 mice (37.5%) with no further tumours emerging over the next ten months of observation ( Fig 3A) . The T-ISC frequency calculated using the L-Calc software for limiting dilution analysis as in (Korkaya et al, 2012) was significantly higher in the CD44
cell injections yielded tumours, the L-Calc software could not be used to calculate T-ISC frequency. However it is noteworthy that only 60% of 100 cell CD44 þ CD24 neg -injected animals formed tumours, suggesting that T-ISC frequency may also be decreased in this subset in MDA-MB-231 as well (Fig 3C, right) . CD44 þ CD24 lowþ -initiated tumours grew more rapidly than those from CD44 þ CD24 neg cells (data for MDA-MB-231 10,000 cell injections, Fig 3D ; data for DT-22 100,000 cell injections, Fig 6G) . Thus, the T-ISC frequency is higher in the CD44 In the DT-22 model, injection of 100,000 cells of each cell type failed to yield metastasis when tumours were excised at 1 cm and animals followed for a further 10 months. This model proved not to generate metastasis in either nude mice or in NOD-SCID mice, a property not known at the outset of the year-long xenograft experiments executed herein. Thus differences in the metastatic ability of the two cell types assayed could not be evaluated in this model.
CD44
þ CD24 lowþ cells preferentially express metastasis signatures MDA-MB-231 variant lines with discrete metastatic tissue tropisms have been used to define gene expression signatures for lung, bone or brain metastasis (Bos et al, 2009; Kang et al, 2003; Minn et al, 2005) . In particular, the 18-gene lung and 17-gene brain metastasis signatures are clinically relevant because they can be observed in primary breast cancers and predict metastatic outcome (Bos et al, 2009; Minn et al, 2005) . Gene expression profiles of CD44 
þ CD24 lowþ show activated Notch pathways and higher embryonic stem cell gene expression Pathways driving embryonic stem cell self-renewal have been implicated in mammary cancer stem cell maintenance (Liu et al, 2006) . In both MDA-MB-231 and DT-22, greater Notch pathway activation was observed in CD44 þ CD24 lowþ cells, with increased protein levels of the intracellular domains N1-ICD, N2-ICD and N4-ICD ( Fig 4A) . CD44 þ CD24 lowþ cells also showed higher NOTCH1, NOTCH2 and NOTCH4 expression levels than in CD44 þ CD24 neg ( Fig 4B) and increased JAG1 and HEY1 expression (MDA-MB-231, Fig 4C) . Interestingly, in sorted MDA-MB-231 the relative expression levels of NOTCH1 and NOTCH2 genes were higher than those of NOTCH3 and NOTCH4 as assayed by q-PCR (MDA-MB-231, Fig 4B, top) . To confirm Notch pathway activation, a profile of genes upregulated following release from gamma-secretase inhibition was characterized by gene expression arrays. CD44 þ CD24 lowþ cells from MDA-MB-231 showed significant overexpression of this Notch activation signature compared to CD44 þ CD24 neg ( Fig 4D) . Embryonic transcription factors Sox2 and Nanog are required for embryonic stem cell (ES) self-renewal (Li, 2010 Table S1 ). Thus, ES transcription programs are preferentially upregulated in the CD44 þ CD24 lowþ subpopulation over
Self-renewal in CD44 þ CD24 lowþ involves Notch1 mediated
Sox2 activation
Since both NOTCH pathway activation and Sox2 levels were upregulated in CD44 þ CD24 lowþ compared to CD44 þ CD24 neg , the relationship between them and their importance to sphereforming ability, a proxy assay of self-renewal was further investigated. Notably, N1-ICD transduction into immortalized HC-11 mammary epithelial cells caused >20-fold increase in SOX2 expression while other Notch isoforms did not (Fig 5A) . The SOX2 promoter in human and murine cells contains multiple Notch consensus motifs. ChIP analysis demonstrated N1-ICD binding to two different SOX2 promoter sites in HC-11 ( Fig 5B) . Similarly, N1-ICD overexpression in MDA-MB-231 increased both SOX2 expression by qPCR and N1-ICD-binding to the SOX2 promoter on ChIP assays (Fig 5C-E) . MDA-MB-231-N1-ICD showed increased frequencies of mammosphere forming cells, CD44 þ CD24 lowþ and ALDH1 þ cells. Notably all of these were reduced by SOX2 knockdown (Fig 5F-H) . MDA-MB-231 cell cycle profiles ( Fig 5I) and proliferation curves over 12 days ( Fig 5J) were unchanged by either N1-ICD overexpression or SOX2 knockdown. Thus, the effects of N1-ICD overexpression and SOX2 knockdown on sphere formation were not merely attributable to effects on cell proliferation. These data suggest that Notch1 critically upregulates SOX2, to promote CD44 þ CD24 lowþ cell self-renewal (see also Fig 6F) .
Differential sensitivity to g-secretase inhibitor in T-ISC populations Notch pathway activation in T-ISC has prompted clinical trials of gamma-secretase inhibitor (GSI) drugs for various cancers (Wang et al, 2009 ). The GSI, RO4929097 a novel, well-tolerated drug that is in clinical trials, significantly reduced N1-ICD in CD44 þ CD24 lowþ from both MDA-MB-231 and DT22, and reduced Sox2 (Fig 6A and C) Fig S6G) .
To ensure that effects of RO4929097 on sphere formation did not result from growth or cell cycle arrest, cell cycle profiles were assayed after 48 h of drug and drug effects on cell numbers over time were assayed over 12 days in culture. Cell cycle and proliferation curves of sorted populations were similar with and without RO4929097 treatment in both DT-22 and MDA-MB-231 ( Fig 6F and Supporting Information Fig S6H-J) .
Differences in RO4929097 response between CD24 low and negative cells were further investigated in vivo with (Fig 8A and B) . Furthermore, the proportion of CD24 lowþ cells in the progeny of N1-ICD-CD44 þ CD24 lowþ was significantly higher than in their respective vector controls over this period (Fig 8C) . Expression of N1-ICD was documented by western blot in both CD24 neg and CD24 lowþ sorted populations transduced with N1-ICD ( Fig 8D) .
DISCUSSION
While many solid tumours appear to be driven by T-ISCs, emerging data suggest that phenotypically distinct subsets exist within T-ISC populations (Meyer et al, 2010; Patel et al, 2012; Visvader & Lindeman, 2012) enrichment score and p-value shown in upper left (see also bone mets signature and similar GSA for sorted DT-22 in Supporting Information Fig S4) . properties and its combined enrichment together with surface CD44 þ CD24 neg/low yields a highly tumourigenic population (Ginestier et al, 2007) . The CD44 þ CD24 neg/low primary human breast cancer population is enriched by taxane chemotherapy (Li et al, 2008) , and exhibits distinct gene expression profiles, prognostic of poor patient outcomes (Creighton et al, 2009; Liu et al, 2007; Shipitsin et al, 2007; Tsunoda et al, 2011 The difficulty of isolating sufficient T-ISCs from primary cancers to permit their molecular characterization has hampered efforts to define pathways critical for T-ISC self-renewal, therapy resistance and metastasis. The present study used not only TNBC lines, but also confirmed findings in human breast cancer cultures at early passage. Early passage patient tumour cultures -while an imperfect substitute for primary tumour analysispermitted molecular assays in T-ISC subsets requiring large cell numbers that are not feasible in primary cancers. It is worth noting that not all TNBC lines and DTs assayed exhibit the dominant CD44/CD24 marker pattern evaluated herein. Present work addressed only the CD44 þ CD24 neg/low subset of TNBC.
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Further investigation is required to determine its relevance to T-ISC in other breast cancer types.
In all three models assayed, CD44 represent phenotypic conversion within a cancer population from a lower to a greater self-renewal potential (discussed further below). These reproducible patterns seen not only in MDA-MB-231, but also in two independent primary TNBC tumour-derived cultures, support a lineage relationship rather than random T-ISC heterogeneity.
The genetic plasticity and aberrant differentiation within cancer cell populations would permit clonal evolution within T-ISC populations, but do not preclude the existence of abortive developmental hierarchies that could contribute to heterogeneity. While other explanations are possible, our data are compatible with a hierarchy such as what has been observed in human leukaemia stem cell subsets (Goardon et al, 2011) , colon (Bu et al, 2013 ) and liver cancer T-ISC (Lee et al, 2011) . Further evidence for the existence of stem-like cancer cells giving rise to clonally related cells with reduced self-renewal capacity was recently provided by lineage tracing in squamous skin papilloma (Driessens et al, 2012) . Present data support the notion that precursor-progeny relationships can exist in T-ISC populations, yielding subsets that differ in self-renewal and, potentially, in the ability to establish metastasis .
CD24 may be a marker of metastatic potential. Its expression is increased in breast and bladder cancer metastasis compared to primaries and confers poor prognosis (Athanassiadou et al, 2009; Bircan et al, 2006; Overdevest et al, 2011; Shipitsin et al, 2007) and CD24 knockdown abrogates metastasis in bladder cancer (Overdevest et al, 2011 ). Present data link low level surface CD24 to metastatic potential in TNBC. In the MDA-MB-231, as few as 100 CD44 þ CD24 lowþ cells yielded orthotopic tumours that generated multi-organ metastasis and lung micrometastasis, while tumours from up to a half million CD44 failed to metastasize. Moreover, CD44 þ CD24 lowþ cells in both MDA-MB-231 and DT-22 showed greater motility and invasion, and preferential expression of gene profiles observed in breast cancers metastatic to lung (Minn et al, 2005) or brain (Bos et al, 2009 ) and that characterize bone metastasis (Kang et al, 2003) . A T-ISC hierarchy with progressive loss of both CD24 and metastatic potential was also observed in a hepatocellular cancer, in which a highly metastatic CD24 þ T-ISC population gave rise to CD24 neg cells that failed to metastasize (Lee et al, 2011) . While present work provides novel evidence for a putative metastatic hierarchy within breast cancer T-ISC in the MDA-MB-231 line, this remains to be confirmed in additional models since DT-22 does not form tumours that metastasize. Present data provide not only an example of heterogeneity in T-ISC of TNBC, but also in molecular pathways and susceptibility to therapeutic targeting. Notch family members play complex and critical roles in fate determination in mammogenesis (Bouras et al, 2008; Raouf et al, 2008; Sale et al, 2013) and are implicated in breast cancer stem cell self-renewal (Harrison et al, 2010; Sansone et al, 2007; Wang et al, 2009 ). NOTCH1 and NOTCH4 pro-viral integration sites mediate mammary tumour formation (Dievart et al, 1999; Gallahan & Callahan, 1987) , Notch4 is upregulated in T-ISC in primary non-invasive (Farnie et al, 2007) and invasive ER positive breast cancers (Harrison et al, 2010) and Notch1 overexpression in breast cancer correlates with worse prognosis (Reedijk et al, 2005; Stylianou et al, 2006 ).
Here we observed higher NOTCH 1, 2 and 4 gene expression in CD44 þ CD24 lowþ cells in MDA-MB-231 and higher levels of N1-ICD, N2-ICD and N4-ICD in both DT-22 and MDA-MB-231 models. Expression profiling showed that Notch driven genes, ES signature genes (Assou et al, 2007) , genes targeted by Nanog, Oct4 and Sox2 (NOS targets) and a subset of these with transcriptional function (NOS-TFs; Boyer et al, 2005) were preferentially expressed by CD24 lowþ compared to CD24 neg cells. Moreover, Sox2 and Nanog proteins were higher in the Notch-activated CD24 lowþ cells, leading us to investigate the link between Notch and Sox2. Sox2 is a driver of ES self-renewal and may play a role in human cancers (Leis et al, 2011; Nakatsugawa et al, 2011; Sarkar & Hochedlinger, 2013; Xiang et al, 2011) . Notch inhibition reduced Sox2, sphere and colony formation, and in vivo tumour growth exclusively in the CD44 þ CD24 lowþ population, without affecting global cell proliferation. Of the four different Notch genes, only N1-ICD overexpression significantly induced SOX2 in our mammary cell models, and N1-ICD bound the SOX2 promoter in both. Moreover, N1-ICD overexpressing MDA-MB-231 showed a Sox2-dependent increase in the proportions of ALDH1 þ and of CD44 þ CD24 lowþ cells, and in sphere formation, suggesting that Notch1 critically activates SOX2 to drive T-ISC self-renewal in these ER negative breast cancer models. Heterogeneity in driving pathways and in the phenotypes of T-ISC has become increasingly apparent (Patel et al, 2012; Schober & Fuchs, 2011; Visvader & Lindeman, 2012) . T-ISC of different surface phenotypes and metastatic ability have been shown to co-exist in pancreatic (Hermann et al, 2007) , colon (Pang et al, 2010) and liver cancer models (Lee et al, 2011; Yang et al, 2008) . Recent work by Kim et al showed that tumour initiating cells in breast cancers of either basal or luminal phenotypes co-exist, with the latter generating more invasive tumours. They also provide evidence that basal-like cancer cells with stem cell traits may give rise to progeny cells with luminal phenotype but not vice versa and cells with luminal markers can initiate tumours .
The present study provides evidence for two phenotypically distinct populations within the TNBC CD44 þ CD24 neg/low , in
population. We also show evidence for phenotypic heterogeneity within the CD44 þ CD24 lowþ population which comprises subsets of ESA þ and ESA À and ALDH1 þ and ALDH1 À cells with different levels of self-renewal as evidenced by limiting dilution sphere assays. Whether precursor-progeny relationships exist within the ESA and ALDH1-based subgroups is yet unknown. ALDH1 activity is very infrequent in CD44 þ CD24 neg/low breast cancer cells (Charafe-Jauffret et al, 2009; Croker et al, 2008; Ginestier et al, 2007) , and populations enriched for both aldefluor activity and CD44 þ CD24 neg/low show a high T-ISC frequency (Ginestier et al, 2007) . It is noteworthy that our ALDH1 þ CD44 þ CD24 lowþ cells showed the greatest abundance of sphere forming cells and also the greatest responsiveness to Notch pathway inhibition. Several groups have presented evidence for potential phenotypic conversion within marker-defined populations (Meyer et al, 2009 ). In tert-immortalized and oncogene transformed HMEC models, CD44 negative cells have been shown to generate CD44 positive progeny suggesting that more "differentiated cells" can revert to a more primordial stem-like precursor (Chaffer et al, 2011) . Different subsets within ER negative breast cancer lines sorted by CD44, CD24 and ESA status appear to 
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Cell Index undergo transitions compatible with a model of stochastic phenotypic conversion (Gupta et al, 2011 ). Here we show that N1-ICD overexpression not only increased CD24 lowþ cells, suggesting an increase in self-renewal/symmetric division, but also led to a low rate of conversion of CD44 þ CD24 neg cell to CD44 þ CD24 lowþ , an event we have not observed spontaneously in culture over several years. Interestingly, xenografts generated from sorted CD44 þ CD24 neg DT-22 cells consistently contained 2-8% CD44 þ CD24 low cells in all of 18 tumours, raising the possibility of a niche-induced inter-conversion in vivo. Taken together, these observations raise the intriguing possibility that the tumour microenvironment may regulate the phenotypic heterogeneity present within tumour initiating stem cells as observed in other systems (Lu et al, 2013 ). An important implication of heterogeneity within malignant stem cell populations is that more primitive stem cells may have not only a greater metastatic propensity, they may also differ from their bulk progeny and escape therapy to re-populate. The importance of the Notch pathway to mammogenesis and mammary cancer has led to the clinical development of Notch inhibitors (Morgan et al, 2013) , several of which are in clinical trials. Notch inhibitors have been shown to augment pre-clinical efficacy of estrogen receptor blockade , trastuzumab and radiation (Phillips et al, 2006) , and enhance chemotherapy response through depletion of stem cells in preclinical models (Qiu et al, 2013) and clinical trials (Schott et al, 2013) . They may also have particular efficacy in TNBC (Clementz et al, 2011; O'Toole et al, 2013) . Loss of experimental brain metastasis following Notch1 knockdown in xenograft models lends support for Notch-targeted therapies (McGowan et al, 2011) . T-ISC heterogeneity may limit the efficacy of therapies that oppose Notch signalling. The two TNBC T-ISC populations characterized herein, differed notably in their responses to GSI. RO4929097, a GSI in clinical trials for cancer, had no effect on tumours derived from CD44 
MATERIALS AND METHODS
Cell lines and primary dissociated tumour cell cultures
MDA-MB-231-luc were cultured as described in Minn et al (2005) . Primary dissociated breast tumour (DT) cultures were isolated by density gradient centrifugation after mechanical dissociation of primary triple negative breast cancers and propagated as described (Bayliss et al, 2007) . are from basal subtype tumours as defined by microarray profiling, DT-28 shows a basal/epithelial phenotype, DT-13 is in the HER2 group, and DT-16 has a luminal B expression profile. DT-21 and DT-23 have expression profiles of cancer associated fibroblasts. MCF-10A is a spontaneously immortalized nontumourigenic human mammary epithelial line. All DTs were grown in IMEM with 10% FBS, used between population doubling 3-30 and passaged 1:2. Established lines were grown in DMEM with 10% FBS.
Flow cytometric assays
Antibodies specific to human cell surface markers: phycoerythrin (PE)-conjugated anti-human CD24 mAb, allophycocyanin (APC)-conjugated anti-human CD44 mAb (BD Pharmingen, CA) and FITC-conjugated mAb to human ESA (Biomeda) were used as in (Fillmore & Kuperwasser, 2008) . Flow cytometry for ALDH1 staining as in (Ginestier et al, 2007) .The gating strategy for isolating CD44
þ was as shown in Fig 1F and G. Cell cycle distribution was assayed by bromodeoxyuridine (BrdU) pulse labelling and flow cytometry as described in (Larrea et al, 2009 ).
3 Figure 6 . Gamma-secretase inhibitors target the CD44 in Supporting Information Fig S6G) . F. Cell cycle profiles of sorted DT-22 populations after 48 h AE10 mM RO were unchanged. Cell cycle profiles and proliferation curves of sorted populations were similar with and without RO treatment in MDA-MB-231 and DT-22 (see Supporting Information Fig S6H-J 
Sphere formation assay and growth in soft agar
Mammosphere assays were as described in Dontu et al (2003) , using 10,000 cells/6-well plates. Spheres >75 mm were counted at 7-10 days. For serial sphere assays, spheres were counted, collected by centrifugation, dissociated with trypsin, re-seeded and evaluated as above. Soft agar colonies were seeded at 10,000 cells per ml of soft agar, stained with 0.1% crystal violet and >75 mm counted at 3-4 weeks.
Drug effects on proliferation
Flow sorted CD44 þ CD24 neg and CD44 þ CD24 lowþ populations were treated with or without GSI drugs DAPT 5 (mM) and RO4920927 (10 mM) for 48 h prior to flow cytometry for cell cycle distribution as described (Larrea et al, 2009 (10 mM) and viable cells were counted at 4, 8 and 12 days with drugs renewed every 4 days.
Western analysis
Westerns were as described (Ginestier et al, 2007) , using antibodies to cleaved Notch1, Sox2, Nanog and b-actin (Cell Signaling Tech, MA). Antibodies to Notch2-ICD, Notch3-ICD and Notch4-ICD were from Abcam.
Chromatin immunoprecipitation assay
ChIP assays were as described (Assou et al, 2007) and used anti-cleaved Notch1 antibody or control IgG to precipitated DNA À770 to À616 from the human SOX2 promoter start site. See human and mouse PCR primers in Supporting Informaton Methods.
In vivo tumourigenicity
Sorted cells from MDA-MB-231-luc (500,000, 100,000, 10,000, 1000 or 100) were injected in 0.05 ml matrigel into one inguinal mammary fat pad of 4-to 6-week-old Balb/C nude mice (Charles River) and tumours measured twice weekly. Tumours from the 500,000 cell group were excised at 1 cm diameter and followed for metastasis. All others were excised per Animal Care and Use Committee or at 100 days if no tumour arose.
DT-22 cells were luciferase tagged and 100,000, 10,000 or 100 sorted cells were xenografted into nude mice (n ¼ 10-12/group). When 100,000 cells formed palpable tumours (mean 70 mm 3 ), animals were treated with either vehicle or RO4929097 (Selleck Chemicals) 30 mg/ kg/day for 14 days as in (Luistro et al, 2009 ; n ¼ 8/group) and measured twice weekly. Bioluminescence images were acquired by IVIS as in Research Article www.embomolmed.org Functional heterogeneity in breast CSCs (Minn et al, 2005) with Living Image 3.0 software (Xenogen Caliper Life Sciences). Tumours were excised at 1.2 cm diameter and single-cell suspensions prepared as in (Charafe-Jauffret et al, 2009), CD44 and CD24 stained and analysed by flow cytometry. Following primary tumour excision, none of the DT-22-derived tumours yielded metastasis over 9 months of follow-up.
Microarray data acquisition, processing and gene set enrichment analysis RNA was isolated with miRNeasy kit (Qiagen) and quantified by Nanodrop 8000 Spectrophotometer (Thermo Scientific, Wilmington) and quality verified by RNA 6000 Nano kit (Agilent, Santa Clara, CA) on a Bioanalyzer 2100 and expression analysis used the Illumina platform (see Supporting Information Methods). Expression data of gene sets from previously described lung, bone and brain metastasis gene signatures were obtained from NCBI Gene Expression Omnibus (accession numbers GSE2603 and GSE12237) and embryonic stem cell transcriptional programs were obtained from ArrayExpress (http:// www.ebi.ac.uk/arrayexpress) under the accession designation E- WMIT-5 (Ben-Porath et al, 2008; Bos et al, 2009; Kang et al, 2003; Minn et al, 2005) . In the case of the NOTCH targets, this gene set was defined by GSI washout of a metastatic MDA-MB-231 variant (see Supporting Information Methods).
Microarray data processing and analysis were performed as described (Minn et al, 2005) using R language and environment for statistical computing version 2.13 and Bioconductor version 2.8. gene set analysis (GSA) was performed using the GSA R package version 1.03.
Gene sets tested were obtained from the original publications (BenPorath et al, 2008; Bos et al, 2009; Charafe-Jauffret et al, 2009; Creighton et al, 2009; Kang et al, 2003; Liu et al, 2007; Minn et al, 2005) . In all cases, a two-class paired comparison between CD24 neg and CD24
low cells was applied using the maxmean statistic and restandardization based on all microarray data set genes. Gene sets showing positive or negative enrichment were significant if false discovery rates and nominal p-values were <0.05 using 1000 permutations. See Supporting Information Methods for details.
Automated migration and invasion assays
Automated transwell migration and invasion assays used the RealTime Cell Analysis (RTCA) system from xCELLigence. For both assays, 20,000 cells were seeded onto a semipermeable membrane without matrigel (migration) or with matrigel (invasion) in the upper chamber in serum-free medium, with 10% FBS added in the bottom chamber. Cell movement across the membrane was measured over 48 h.
N1-ICD overexpression and siRNA transfection
HC-11 or MDA-MB-231 were transduced with pBABEpuro-N1-ICD retrovirus. For Sox2 knockdown, scrambled controls or siRNAs against Sox2 (Santa Cruz) were transfected into MDA-MB-231 with Lipofectamine 2000.
Statistical analysis
Data were presented as mean AE SE from at least three experiments and used two-tailed Student's t tests to detect differences. Comparative
The paper explained PROBLEM:
Most cancer patient death is due to progression of visceral metastasis resistant to chemo and radiation therapies. Breast and other common cancers appear to arise from stem-like cells that self-renew and give rise to progeny with less robust selfrenewal. These tumour-initiating stem cells or cancer stem cells (T-ISC/CSCs) express discrete surface markers, can generate tumours from as few as 10-100 cells and may have greater ability to form metastasis and resist treatment than the bulk tumour population in experimental models. IMPACT:
Treating cancers with stem cell targeted therapies may be more complicated than we thought. While GSI drugs hold promise for targeting breast CSCs, heterogeneity within the T-ISC subpopulation could limit their therapeutic efficacy. CSC subpopulations within a tumour may be driven by different molecular pathways and thus differ in their ability to respond to drugs. These findings support further phenotypic and molecular characterization of distinct T-ISC subpopulations, since they may illuminate limitations of current therapy and open new avenues for more effective cancer treatment.
analysis of growth curves (http://bioinf.wehi.edu.au/software/compareCurves) was applied to tumour growth curves over a series of multiple time points using the statmod software package. TISC frequency was calculated using the L-Calc software http://www.stemcell.com/tutorials/lcsetup.exe (Stem Cell Technologies). Microarray analysis is described above and in Supporting Information Methods and used MIAME standards. 
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